Form 4: CompoSecure Director Kevin Moriarty Granted Significant Stock Options

CompoSecure, Inc. Director Kevin M. Moriarty was granted 56,570 stock options with an exercise price of $14.21, vesting over four years.

Summary

• Kevin M. Moriarty, a Director of CompoSecure, Inc. (CMPO), was granted a total of 56,570 stock options.
• The grant consists of two separate tranches: 29,491 stock options and 27,079 stock options.
• The exercise price for all granted options is $14.21 per share.
• These stock options will vest in equal annual installments of 25% each, beginning on July 12, 2026.
• Subsequent vesting dates will occur on the first, second, and third anniversaries of July 12, 2026 (i.e., July 12, 2027, July 12, 2028, and July 12, 2029).
• The expiration date for these stock options is July 12, 2035.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive mechanism for aligning interests and incentivizing long-term performance, with no apparent negative implications.

Positives

• The granting of stock options to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The options have a 10-year expiration period, providing a substantial window for the director to realize potential value if the company's stock price appreciates.

Risks

• The value of the granted stock options is contingent on CompoSecure's Class A Common Stock price exceeding the exercise price of $14.21 per share. If the stock price remains below this threshold, the options may expire worthless.
• Future exercise of these options could lead to minor dilution for existing shareholders as new shares of Class A Common Stock are issued.

Future Outlook

The equity grant signifies a long-term incentive for the director, aligning their future financial interests with the company's stock performance and strategic objectives.

Industry Context

Equity grants, such as stock options, are a standard component of compensation packages for directors and executives across various industries, including technology and financial services. These grants are designed to attract, retain, and motivate key personnel by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in corporate governance for publicly traded companies, comparable to compensation structures observed at other payment technology or security-focused firms.
• A 10-year expiration period for stock options is typical for long-term incentive plans across many sectors.
• The four-year annual vesting schedule is also a widely adopted standard for equity awards, similar to practices at major technology companies.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to improved long-term performance. There is a minor potential for dilution upon exercise of the options.
• Management/Employees: This grant reflects standard compensation practices for key personnel, which can contribute to overall morale and retention.

Next Steps

• Future vesting events for the stock options are scheduled for July 12, 2026, July 12, 2027, July 12, 2028, and July 12, 2029.
• The director may choose to exercise these options if CompoSecure's stock price exceeds the exercise price before the options' expiration on July 12, 2035.

Key Dates

Keywords

CompoSecure, CMPO, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4, Beneficial Ownership